A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura
A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Usual care is the open-label control arm. Dose of ubrogepant (50 mg or 100 mg) will be double-blind for active treatment arms.
Inclusion Criteria:
-Completed study UBR-MD-01(NCT02828020) or UBR-MD-02(NCT02867709).
Exclusion Criteria:
Palm Beach Gardens, Florida 33410, United States
Overland Park, Kansas 66210, United States
Las Vegas, Nevada 89117, United States